Cresco Labs Reports Q4 2020 Revenues Of $162.3 Million, Net Loss Of $23.4 Million

Cresco Labs (CSE: CL) this morning reported its fourth quarter and full year 2020 financial results. The company recorded fourth quarter revenues of $162.3 million, along with a net loss of $23.4 million. For the full year, revenues came in at $476.3 million, while the company posted a net loss of $36.6 million.

The fourth quarter saw the company beat consensus estimates for revenue, which sat at $161.38 million, while also beating on adjusted EBITDA, which was estimated at $48.06 million, compared to the $50.0 million realized by the company. Full year results also beat consensus on both measures, with revenue consensus sitting at $475.5 million and adjusted EBITDA consensus at $114.12 million. The company reported full year adjusted EBITDA of $116.0 million.

Looking at the fourth quarter, revenues grew from $153.3 million in the third quarter to $162.3 million in the fourth. Cost of sales amounted to $89.3 million, resulting in a gross profit before fair value adjustments of $73.0 million. Post-fair value adjustments the firm saw gross profit jump to $95.7 million, which the company pegged as being a 59.0% margin, compared to 55.2% in the prior quarter.

Total expenses meanwhile amounted to $73.7 million, with SG&A amounted to $68.1 million, a significant climb from the $46.8 million recorded in the third quarter. Depreciation and amortization amounted to a further $5.6 million in expenditures.

Other expenses of $31.1 million ultimately put the company in the red. Cresco recognized $10.4 million in interest expenses during the quarter, while other expenses hit $19.8 million, resulting in a net loss of $23.4 million overall for the quarter.

Full financials have yet to be filed for the quarter, with a brief snapshot being provided for the balance sheet. Cash and cash equivalents for the quarter amounted to $136.3 million, a notable improvement from the $57.7 million recorded in the third quarter. Total current assets overall improved from $257.1 million to $361.8 million. To current liabilities meanwhile declined from $243.7 million to $194.6 million.

Cresco Labs last traded at $16.46 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why $50 Silver, $4000 Gold Might Be Closer Than Anyone Thinks | Bradley Langille – GoGold Resources

Why Silver’s True Price Could Be Much Higher | Joaquín Marias – Argenta Silver

Gold Enters A ‘Stronger For Longer’ Phase | Richard Young – i-80 Gold

Recommended

Discovery Silver in Advanced Talks to Acquire Barrick’s Last Canadian Gold Mine

Emerita Reports Aznalcollar Public Tender Trial Hearings Have Concluded, Verdict Expected This Fall

Related News

Cresco Labs Lowers Q4 2021 Revenue Guidance After Reducing Third Party Agreements

Cresco Labs (CSE: CL) announced on Thursday that it is exiting exclusive distributorship agreements of certain...

Friday, October 1, 2021, 09:22:00 AM

Haywood Drops Cresco Labs Price Target To $24.50

Cresco Labs (CSE: CL) reported its first-quarter financial results this past week. The company announced...

Monday, May 31, 2021, 11:40:00 AM

Cresco Labs Posts 1.8% Sequential Revenue Growth In Second Quarter

Cresco Labs (CSE: CL) was the latest cannabis operator to report earnings this morning for...

Wednesday, August 17, 2022, 08:15:24 AM

Canaccord Lowers Cresco Labs’ Price Target To $9.50

On May 18th, Cresco Labs (CSE: CL) reported its first quarter financial results. The company...

Saturday, May 21, 2022, 03:02:00 PM

Origin House Secures Additional Short Term Loan

Origin House (CSE: OH) announced this morning that it had secured an additional short term...

Friday, September 20, 2019, 09:51:29 AM